Helius Medical Technologies Inc Class A Stock News

HSDT Solana Company's Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors

Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation

NEWTOWN, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its first acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana Blockchain. The Company now holds over 760,190 SOL, with an average cost basis of $231. The...

Preeminent SOL-backed treasury vehicle - with potential to raise over $1.25 billion aggregate gross proceeds - unlocks capital markets to accelerate Solana's growth The financing drew participation from leading investors across traditional finance and crypto, including Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless, Laser Digital, Has...

Preeminent SOL-backed treasury vehicle - with potential to deliver over $1.25 billion - unlocks capital markets to accelerate Solana's growth The offering was led by institutional and crypto-native investors such as Pantera Capital, Summer Capital, and other prominent backers including Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless, L...

NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication fo...

NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicatin...

NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on June 30, 202...